Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy
Authors
Keywords
-
Journal
LEUKEMIA
Volume 27, Issue 8, Pages 1715-1721
Publisher
Springer Nature
Online
2013-02-18
DOI
10.1038/leu.2013.50
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma
- (2011) Noopur Raje et al. CLINICAL CANCER RESEARCH
- Crosstalk between Nodal/Activin and MAPK p38 Signaling Is Essential for Anterior-Posterior Axis Specification
- (2011) Melanie Clements et al. CURRENT BIOLOGY
- AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
- (2010) L Santo et al. ONCOGENE
- Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
- (2010) S. Vallet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
- (2009) P. Richardson et al. BLOOD
- RAP-011, a soluble activin receptor type IIA murine IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone loss and skeletal metastases in a mouse model of metastatic breast cancer
- (2009) A.W. Mulivor et al. BONE
- High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties
- (2009) S. Pozzi et al. CLINICAL CANCER RESEARCH
- Mechanism of action of lenalidomide in hematological malignancies
- (2009) Venumadhav Kotla et al. Journal of Hematology & Oncology
- Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
- (2009) N Raje et al. LEUKEMIA
- Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide
- (2009) Monica De Matteo et al. LEUKEMIA RESEARCH
- Dlx5, a Positive Regulator of Osteoblastogenesis, is Essential for Osteoblast-Osteoclast Coupling
- (2008) Nadeem Samee et al. AMERICAN JOURNAL OF PATHOLOGY
- Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women*
- (2008) Jon Ruckle et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
- (2008) I Breitkreutz et al. LEUKEMIA
- Thalidomide and lenalidomide: Mechanism-based potential drug combinations
- (2008) Sonia Vallet et al. LEUKEMIA & LYMPHOMA
- A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity
- (2008) R. S. Pearsall et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started